Agilent Technologies, Inc. (NYSE:A) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Monday, July 31st.
Other research analysts have also issued research reports about the stock. Robert W. Baird increased their target price on shares of Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 24th. Deutsche Bank AG reaffirmed a “buy” rating and set a $58.00 target price (up previously from $56.00) on shares of Agilent Technologies in a research note on Sunday, April 2nd. Morgan Stanley increased their target price on shares of Agilent Technologies from $65.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 24th. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research note on Tuesday, May 16th. Finally, Barclays PLC reissued a “buy” rating and issued a $67.00 price objective on shares of Agilent Technologies in a research note on Wednesday, July 19th. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Agilent Technologies currently has an average rating of “Buy” and a consensus price target of $60.12.
Agilent Technologies (NYSE:A) traded up 1.30% during trading on Monday, reaching $59.33. The company’s stock had a trading volume of 1,511,552 shares. The company has a 50-day moving average of $60.10 and a 200 day moving average of $55.69. Agilent Technologies has a one year low of $42.92 and a one year high of $61.84. The firm has a market cap of $19.06 billion, a PE ratio of 33.35 and a beta of 1.30.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, May 22nd. The medical research company reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.10. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period last year, the business earned $0.44 earnings per share. Agilent Technologies’s revenue was up 8.1% compared to the same quarter last year. Analysts expect that Agilent Technologies will post $2.23 EPS for the current fiscal year.
In related news, Director James Cullen sold 15,482 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $59.04, for a total transaction of $914,057.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $59.86, for a total value of $2,993,000.00. The disclosure for this sale can be found here. Insiders sold a total of 112,608 shares of company stock valued at $6,737,509 in the last three months.
Several institutional investors have recently added to or reduced their stakes in the stock. Kentucky Retirement Systems purchased a new position in shares of Agilent Technologies during the fourth quarter valued at about $1,072,000. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in shares of Agilent Technologies during the fourth quarter valued at $478,000. Chevy Chase Trust Holdings Inc. raised its stake in shares of Agilent Technologies by 2.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 280,055 shares of the medical research company’s stock valued at $14,807,000 after buying an additional 6,577 shares in the last quarter. CENTRAL TRUST Co raised its stake in shares of Agilent Technologies by 15.3% in the first quarter. CENTRAL TRUST Co now owns 2,994 shares of the medical research company’s stock valued at $158,000 after buying an additional 398 shares in the last quarter. Finally, New England Research & Management Inc. bought a new stake in shares of Agilent Technologies during the first quarter valued at $283,000.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.